Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

On September 13, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) (Free ESMO Whitepaper) in Barcelona, Spain, Sept. 13-17, 2024 (Press release, Guardant Health, SEP 13, 2024, View Source [SID1234646602]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data on the Guardant Reveal minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360 for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity platform for response monitoring in advanced non-small cell lung cancer (NSCLC).

"Our latest data featured at ESMO (Free ESMO Whitepaper) further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatment management across multiple tumor types," said Craig Eagle, M.D., chief medical officer at Guardant Health. "We look forward to sharing how Guardant tests can contribute to improved outcomes across all stages of cancer care."

Complete list of Guardant Health and collaborator presentations at ESMO (Free ESMO Whitepaper) 2024

Abstract

Title (Hall 6, unless otherwise noted)

Product

Saturday, September 14 | 9:00 – 17:00

1295P

EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI

Guardant Infinity

Sunday, September 15 | 9:00 – 17:00

127P

Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors

Guardant 360

Monday, September 16 | 9:00 – 17:00

418P

Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer

Guardant 360

419P

Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer

Guardant 360

Monday, September 16 | 17:04 – 17:16

509O

Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch

repair locally advanced rectal cancer (pMMR LARC): first results of NO-CUT Trial

Proffered Paper Session: Presidential Symposium III: Eyes to the future, Barcelona Auditorium, Hall 2

Guardant Reveal

The full abstracts for Guardant Health and a list of all abstracts being presented at the ESMO (Free ESMO Whitepaper) Congress can be found on the ESMO (Free ESMO Whitepaper) website.

For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit Guardant on-site at booth #510.

Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China for treatment of relapsed/refractory multiple myeloma

On September 13, 2024 GlaxoSmithKline reported that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has granted Breakthrough Therapy Designation (BTD) for Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) for the treatment of relapsed or refractory multiple myeloma (Press release, GlaxoSmithKline, SEP 13, 2024, View Source [SID1234646569]). NMPA BTD is intended to expedite the development of therapies for serious and life-threatening diseases for which there are no existing treatments or where initial evidence has shown an improvement in patient outcomes over available treatment options.2

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: "Breakthrough Therapy Designation in China underscores the potential for Blenrep to redefine outcomes for patients with multiple myeloma at or after their first relapse. We look forward to continuing to work with the health authority in China and others worldwide to bring Blenrep-based combinations to patients as expeditiously as possible."

BTD was granted based on the interim results of the phase III head-to-head DREAMM-7 trial, which met its primary endpoint, showing statistically significant and clinically meaningful improvements in progression-free survival (PFS) for belantamab mafodotin combined with BorDex compared to daratumumab plus BorDex in relapsed or refractory multiple myeloma.

A positive overall survival (OS) trend was observed but was not statistically significant at the time of interim analysis. Follow-up for OS continues. Results also showed clinically meaningful improvements across all other secondary efficacy endpoints, including deeper and more durable responses compared to the standard of care combination. The safety and tolerability profile of the belantamab mafodotin combination in the DREAMM-7 trial was broadly consistent with the known profiles of the individual agents.

Multiple myeloma is a growing health concern in China with approximately 30,000 new cases each year.3 The incidence in China has doubled and mortality has increased 1.5-fold in the past three decades.4 This underscores the need for novel, efficacious treatment options for patients in China, particularly those with progressing disease that has become resistant to the current standard of care.

About multiple myeloma
Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable.5,6 There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year.7 Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments.8

About DREAMM-7
The DREAMM-7 phase III clinical trial is a multicentre, open-label, randomised trial evaluating the efficacy and safety of belantamab mafodotin in combination with BorDex compared to a combination of daratumumab and BorDex in patients with relapsed/refractory multiple myeloma who previously were treated with at least one prior line of multiple myeloma therapy, with documented disease progression during or after their most recent therapy.

A total of 494 participants were randomised at a 1:1 ratio to receive either belantamab mafodotin in combination with BorDex or a combination of daratumumab and BorDex. Belantamab mafodotin was scheduled to be dosed at 2.5mg/kg intravenously every three weeks.

The primary endpoint is PFS as per an independent review committee. The key secondary endpoints include OS, duration of response (DOR), and minimal residual disease (MRD) negativity rate as assessed by next-generation sequencing. Other secondary endpoints include overall response rate (ORR), safety, and patient reported and quality of life outcomes.

Results from DREAMM-7 were first presented9 at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Plenary Series in February 2024, shared in an encore presentation at the 2024 ASCO (Free ASCO Whitepaper) Annual Meeting, and published in the New England Journal of Medicine.

About Blenrep
Blenrep is an antibody-drug conjugate comprising a humanised B-cell maturation antigen monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker. The drug linker technology is licensed from Seagen Inc.; the monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa Inc., a member of the Kyowa Kirin Group.

Blenrep is approved as monotherapy in Hong Kong, Israel and Singapore. Refer to the local Summary of Product Characteristics for a full list of adverse events and complete important safety information.

Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights

On September 13, 2024 Celyad Oncology (Euronext: CYAD) (the "Company"), reported its financial results for the first half year 2024 ended June 30, 2024, and provides a business update (Press release, Celyad, SEP 13, 2024, View Source [SID1234646603]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Michel Lussier, interim Chief Executive Officer of Celyad Oncology, commented: "Celyad Oncology continues to make remarkable progress in developing cutting-edge technologies for chimeric antigen receptor (CAR) T-cell therapy. Our groundbreaking multiplex platform is revolutionizing the potential of CAR T-cells, while our pioneering NKG2D-based multispecific CAR T-cell platform is further paving the way to conquer current limitations of this transformative class of immunotherapy."

H1-2024 Business highlights

The Company is pursuing a strategy of continued research and development, with a particular focus on intellectual property (IP). Monetization of its innovative approaches and technologies is a key objective. Celyad Oncology is progressing in this regard and is currently in discussion with potential partners for out-licensing deals;
With its research focus, the Company has made concrete progress by providing proof-of-concept of the multiplex short hairpin RNAs (shRNAs) non-gene edited technology platform and the multispecific NKG2D-based CAR T-cell platform, which provide unique options to tackle the major current limitations of CAR T-cell therapies. Options to further explore or validate these data through strategic partnerships, and/or to incorporate these technologies into clinical CAR-T candidates are actively pursued by the Company;
The Company continues to share and discuss its latest advances at international scientific conferences throughout the first half of 2024 with updated results provided at the 27th ASGCT (Free ASGCT Whitepaper) 1 Annual Meeting and the Recent insights into Immuno-Oncology VIB conference 2.
The Company is also focusing on sharing data and views with the scientific community and has published a review highlighting the interest of non-gene editing technologies for allogeneic CAR T-cell therapies in Cells 3 and another review providing an overview of all engineering strategies to safely drive CAR T-cells into the future in Frontiers in Immunology 4, two well-renowned peer-reviewed scientific journals;
In response to the request expressed by several companies and academic institutions engaged in gene and cell therapies for cardiac applications, the Company has re-initiated the manufacturing and commercialization of C-Cath, an intra-myocardial injection catheter developed and owned by the Company.
H1-2024 operational highlights

Multiplex shRNA non-gene edited technology – The Company developed a chimeric micro-RNA (miRNA) cluster to enable multiplexing of shRNAs, designed for easy, efficient, and tunable downregulation of up to four target genes simultaneously in CAR T-cells.
Data successfully demonstrated the feasibility and effectiveness of the multiplex approach to improve allogeneic CAR T-cell viability by avoiding graft-versus-host disease (GvHD) via knocking down of CD3ζ, avoiding host-versus-graft (HvG) reaction and promoting cell persistence via knocking-down of β2M and CIITA, and avoiding CD95L-induced autophagy via knocking-down of CD95;
Another multiplex cassette focusing on the knock-down of co-inhibitory receptors (PD-1, LAG-3, TIM-3 and CD95) was also developed to decrease the expression of exhaustion markers at the surface of CAR T-cells.
Multispecific NKG2D-based CAR T-cell platform – Different NKG2D-based multispecific CAR T-cells were developed to provide the proof-of-concept that NKG2D ligands (NKG2DL) are valuable targets in a multispecific CAR approach to counteract relapses due to antigen loss or antigen heterogeneity.
PSMA/NKG2DL tandem CAR T-cells, that encompass the extracellular domain of the natural NKG2D receptor fused to an anti-PSMA CAR to overcome antigen heterogeneity and improve anti-tumor efficacy against prostate cancer were developed and demonstrated functionality in vitro against prostate cancer cell lines expressing or not the tumor-associated antigen PSMA;
In vivo proof-of-concept of the company’s CD19/NKG2DL tandem CAR T-cell candidate was also provided in a B-ALL relapse model, showing that this multi-specific CAR T-cell candidate has an enhanced anti-tumor efficacy against heterogeneous lymphoma tumors, or to counteract antigen loss, as compared to currently existing treatment options.
First Half 2024 financial review

As of June 30, 2024, the Company’s Treasury position amounts to €6.2 million.

After due consideration of detailed budgets and estimated cash flow forecasts for the years 2024 and 2025, the Company projects that its existing cash and cash equivalents will be sufficient to fund its estimated operating and capital expenditures into the third quarter of 2025.

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

On September 13, 2024 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), which describes the design and characterization of NVL-655 and details Nuvalent’s approach to rationally targeting ALK (Press release, Nuvalent, SEP 13, 2024, View Source [SID1234646572]). NVL-655 is currently being studied in the ongoing ALKOVE-1 Phase 1/2 clinical trial for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The manuscript, entitled "NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK mutant oncoproteins, including lorlatinib-resistant compound mutations," is published online and can be accessed here: View Source

"Currently available ALK tyrosine kinase inhibitors (TKIs) are important treatment options for patients with ALK-driven lung cancer. However, limitations including treatment-emergent drug resistance, off-target neurological adverse events, and inadequate control of brain metastases, support the need for continued development in this disease," said senior author Alexander Drilon, MD, Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, and investigator in the ALKOVE-1 trial. "As detailed in this publication, preclinical characterization and preliminary clinical data provide a compelling rationale for the ongoing clinical investigation of NVL-655 and evaluation of its potential to address the limitations of available ALK TKIs for patients with ALK-positive NSCLC."

The manuscript details the design principles underlying the activity of NVL-655 against ALK single and compound resistance mutations, including the most commonly occurring resistance mutation, ALK G1202R. Additionally, it outlines a molecular rationale for the selectivity of NVL-655 for ALK over the structurally related tropomyosin receptor kinase (TRK) family, whose inhibition has been associated with neurological adverse events that can be dose limiting. Preclinical characterization of the activity and selectivity of NVL-655 is presented, including in vivo xenograft studies, preclinical assessments of brain penetrance and intracranial activity, and a comparison of eight ALK TKIs across multiple biochemical and cellular assays.

The manuscript further documents three case studies from the ALKOVE-1 trial of patients with ALK fusion-positive lung cancers who had received a range of ALK TKIs, including lorlatinib, and presented with brain metastases or with tumors that harbored ALK G1202R. NVL-655 elicited tumor responses in these patients without accompanying CNS effects attributed to off-target TRK inhibition. These findings support the potential for NVL-655 as a future treatment for these patient populations that may also enhance tolerability through improved selectivity for ALK.

"With this publication in Cancer Discovery, we are pleased to have now also elucidated our focused approach for ALK-positive NSCLC. Along with our parallel lead program for ROS1-positive NSCLC, these selective inhibitors form the foundation for our pipeline of precisely targeted therapies which aim to deliver potential best-in-class activity against recalcitrant targets through solving for multiple, and at times competing, challenges in structure-based drug design," said Joshua Horan, Ph.D., Vice President, Chemistry at Nuvalent. "We are grateful to our collaborators for their contributions to this manuscript and to the continued advancement of NVL-655."

Enrollment is ongoing in the global Phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial, designed with registrational intent. Updated data from the Phase 1 portion of the trial will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2024 in Barcelona, Spain during a Proffered paper session on Saturday September 14, 2024 from 9:30 – 9:40 a.m. CEST.

About NVL-655

NVL-655 is a novel brain-penetrant ALK-selective inhibitor created with the aim to overcome limitations observed with currently available ALK inhibitors. NVL-655 is designed to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with single or compound treatment-emergent ALK mutations such as G1202R. In addition, NVL-655 is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with dual TRK/ALK inhibitors and to drive deep, durable responses for patients across all lines of therapy. NVL-655 has received breakthrough therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more ALK tyrosine kinase inhibitors and orphan drug designation for ALK-positive NSCLC. NVL-655 is currently being evaluated in the Phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial, a first-in-human study of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors (NCT05384626).

MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits

On September 13, 2024 MediLink Therapeutics (MediLink) reported clinical data for YL201, a novel B7H3-targeting antibody drug conjugate (ADC) developed based on MediLink’s Tumor Microenvironment Activable LINker-payload (TMALIN) platform, at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress (Press release, Suzhou Medilink Therapeutics, SEP 13, 2024, View Source [SID1234646573]). This is the first disclosure of clinical data for YL201 featured in an oral presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presented results are from phase I studies (NCT05434234 & NCT06057922) conducted in China and the US to explore the safety and efficacy of YL201 in patients with advanced solid tumors. As shown in the abstract, by August 9 2024, a total of 312 patients were enrolled in the dose escalation and expansion studies with various tumor types, including small cell lung cancer (SCLC, n=79), nasopharyngeal carcinoma (NPC, n=75), and non-small cell lung cancer without actionable genomic alterations (NSCLC without AGAs, n=68). All enrolled patients have been treated with prior standard therapy, and 60% had at least 2 prior treatment lines.

During dose escalation stage, dose limiting toxicities were observed at 2.8 mg/kg (n=1) and 3.0 mg/kg (n=2). For dose expansion, 2.0 mg/kg and 2.4 mg/kg were selected as recommended expansion doses. As of 09 Aug 2024, 276 patients had at least one post-baseline tumor assessment per RECIST V1.1., The overall response rate (ORR) was 44.6%, the disease control rate (DCR) was 83.7%. The median follow-up duration was 5.4 months, and 46% of the patients are still on treatment.

Antitumor activity was observed in multiple solid tumor types. In extensive-stage SCLC patients, among 72 patients who had evaluable tumor assessment, all patients had prior treatment with platinum-based chemotherapy, and 95% had prior treatment with anti-PD-(L)1. The ORR was 68.1% (at dose levels >= 2.0 mg/kg: 70.0%) and the median progress-free survival (mPFS) was 6.2 months (at dose levels >= 2.0 mg/kg: 6.2 months). Also worth mentioning was that in patients with brain metastasis, the ORR was 52.2% and mPFS was 5.3 months, comparable to those of overall population.

In 70 NPC patients with evaluable tumor assessment, the ORR was 48.6% (at dose levels >= 2.0 mg/kg: 48.6%), and mPFS was 7.2 months (at dose levels >= 2.0 mg/kg: 7.2 months). In heavily-treated NPC patients receiving at least 2 prior lines of treatment, the efficacy was also comparable, with ORR of 51.0% and mPFS of 7.0 months.

In NSCLC without AGA, all patients had prior treatment with anti-PD-(L)1 and platinum-based chemotherapy. In the histological subtypes of adenocarcinoma and LELC, ORR were 29.2% and 60.9%, respectively, and mPFS were unmatured and 8.1 months, respectively.

In terms of safety, the grade 3 and higher treatment-related TEAEs (TRAEs) occurred in 51% of the patients, and serious TRAEs occurred in 28%. The most common TRAE were leukopenia (G≥3 29%), anemia (G≥3 22%) and neutropenia (G≥3 30%), while decreased appetite (G≥3 1%) and nausea (G≥3 1%) were the most common non-hematological TRAEs. Only 3 (1%) were reported as treatment related interstitial lung disease.

"We are excited to share the results of YL201 at the ESMO (Free ESMO Whitepaper) Congress," said Dr. Steve Chin, Chief Medical Officer of MediLink. "Clinical data accumulated from a sample size of over 300 patients has solidly demonstrated the antitumor activity of YL201 in multiple solid tumor types, especially in SCLC, NPC, and NSCLC without AGA. Significant improvement was shown in these population compared to historical data of existing standard treatment regimens. Also, YL201 is well tolerated with the most common TRAEs being hematological toxicities, which are deemed to be manageable. We were actively preparing Phase 3 studies of YL201 in SCLC, NPC, etc."

About YL201

YL201 is an innovative antibody-drug conjugate that specifically targets B7-H3. B7-H3 is overexpressed on differentiated malignant cells and cancer-initiating cells of various tumor types, but has a restricted expression in normal tissue, indicating its potential as ADC drug. YL201 has been developed by utilizing MediLink’s Tumor Microenvironment Activable LINker-payload (TMALIN) conjugated with a highly specific B7-H3 antibody. Currently, YL201 is being investigated in four Phase I or II studies, including one multi-national Phase I clinical study.